Cargando…

Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease

Hirayama disease (HD) is characterized by the juvenile onset of unilateral or asymmetric weakness and amyotrophy of the hand and ulnar forearm and is most common in males in Asia. A perception of compliance with previous standards of diagnosis and treatment appears to be challenged, so the review is...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hongwei, Tian, Ye, Wu, Jianwei, Luo, Sushan, Zheng, Chaojun, Sun, Chi, Nie, Cong, Xia, Xinlei, Ma, Xiaosheng, Lyu, Feizhou, Jiang, Jianyuan, Wang, Hongli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844368/
https://www.ncbi.nlm.nih.gov/pubmed/35178023
http://dx.doi.org/10.3389/fneur.2021.811943
_version_ 1784651458997649408
author Wang, Hongwei
Tian, Ye
Wu, Jianwei
Luo, Sushan
Zheng, Chaojun
Sun, Chi
Nie, Cong
Xia, Xinlei
Ma, Xiaosheng
Lyu, Feizhou
Jiang, Jianyuan
Wang, Hongli
author_facet Wang, Hongwei
Tian, Ye
Wu, Jianwei
Luo, Sushan
Zheng, Chaojun
Sun, Chi
Nie, Cong
Xia, Xinlei
Ma, Xiaosheng
Lyu, Feizhou
Jiang, Jianyuan
Wang, Hongli
author_sort Wang, Hongwei
collection PubMed
description Hirayama disease (HD) is characterized by the juvenile onset of unilateral or asymmetric weakness and amyotrophy of the hand and ulnar forearm and is most common in males in Asia. A perception of compliance with previous standards of diagnosis and treatment appears to be challenged, so the review is to update on HD. First, based on existing theory, the factors related to HD includes, (1) cervical cord compression during cervical flexion, (2) immunological factors, and (3) other musculoskeletal dynamic factors. Then, we review the clinical manifestations: typically, (1) distal weakness and wasting in one or both upper extremities, (2) insidious onset and initial progression for 3–5 years, (3) coarse tremors in the fingers, (4) cold paralysis, and (5) absence of objective sensory loss; and atypically, (1) positive pyramidal signs, (2) atrophy of the muscles of the proximal upper extremity, (3) long progression, and (4) sensory deficits. Next, updated manifestations of imaging are reviewed, (1) asymmetric spinal cord flattening, and localized lower cervical spinal cord atrophy, (2) loss of attachment between the posterior dural sac and the subjacent lamina, (3) forward displacement of the posterior wall of the cervical dural sac, (4) intramedullary high signal intensity in the anterior horn cells on T2-weighted imaging, and (5) straight alignment or kyphosis of cervical spine. Thus, the main manifestations of eletrophysiological examinations in HD include segmental neurogenic damages of anterior horn cells or anterior roots of the spinal nerve located in the lower cervical spinal cord, without disorder of the sensory nerves. In addition, definite HD needs three-dimensional diagnostic framework above, while probable HD needs to exclude other diseases via “clinical manifestations” and “electrophysiological examinations”. Finally, the main purpose of treatment is to avoid neck flexion. Cervical collar is the first-line treatment for HD, while several surgical methods are available and have achieved satisfactory results. This review aimed to improve the awareness of HD in clinicians to enable early diagnosis and treatment, which will enable patients to achieve a better prognosis.
format Online
Article
Text
id pubmed-8844368
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88443682022-02-16 Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease Wang, Hongwei Tian, Ye Wu, Jianwei Luo, Sushan Zheng, Chaojun Sun, Chi Nie, Cong Xia, Xinlei Ma, Xiaosheng Lyu, Feizhou Jiang, Jianyuan Wang, Hongli Front Neurol Neurology Hirayama disease (HD) is characterized by the juvenile onset of unilateral or asymmetric weakness and amyotrophy of the hand and ulnar forearm and is most common in males in Asia. A perception of compliance with previous standards of diagnosis and treatment appears to be challenged, so the review is to update on HD. First, based on existing theory, the factors related to HD includes, (1) cervical cord compression during cervical flexion, (2) immunological factors, and (3) other musculoskeletal dynamic factors. Then, we review the clinical manifestations: typically, (1) distal weakness and wasting in one or both upper extremities, (2) insidious onset and initial progression for 3–5 years, (3) coarse tremors in the fingers, (4) cold paralysis, and (5) absence of objective sensory loss; and atypically, (1) positive pyramidal signs, (2) atrophy of the muscles of the proximal upper extremity, (3) long progression, and (4) sensory deficits. Next, updated manifestations of imaging are reviewed, (1) asymmetric spinal cord flattening, and localized lower cervical spinal cord atrophy, (2) loss of attachment between the posterior dural sac and the subjacent lamina, (3) forward displacement of the posterior wall of the cervical dural sac, (4) intramedullary high signal intensity in the anterior horn cells on T2-weighted imaging, and (5) straight alignment or kyphosis of cervical spine. Thus, the main manifestations of eletrophysiological examinations in HD include segmental neurogenic damages of anterior horn cells or anterior roots of the spinal nerve located in the lower cervical spinal cord, without disorder of the sensory nerves. In addition, definite HD needs three-dimensional diagnostic framework above, while probable HD needs to exclude other diseases via “clinical manifestations” and “electrophysiological examinations”. Finally, the main purpose of treatment is to avoid neck flexion. Cervical collar is the first-line treatment for HD, while several surgical methods are available and have achieved satisfactory results. This review aimed to improve the awareness of HD in clinicians to enable early diagnosis and treatment, which will enable patients to achieve a better prognosis. Frontiers Media S.A. 2022-02-01 /pmc/articles/PMC8844368/ /pubmed/35178023 http://dx.doi.org/10.3389/fneur.2021.811943 Text en Copyright © 2022 Wang, Tian, Wu, Luo, Zheng, Sun, Nie, Xia, Ma, Lyu, Jiang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Wang, Hongwei
Tian, Ye
Wu, Jianwei
Luo, Sushan
Zheng, Chaojun
Sun, Chi
Nie, Cong
Xia, Xinlei
Ma, Xiaosheng
Lyu, Feizhou
Jiang, Jianyuan
Wang, Hongli
Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease
title Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease
title_full Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease
title_fullStr Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease
title_full_unstemmed Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease
title_short Update on the Pathogenesis, Clinical Diagnosis, and Treatment of Hirayama Disease
title_sort update on the pathogenesis, clinical diagnosis, and treatment of hirayama disease
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844368/
https://www.ncbi.nlm.nih.gov/pubmed/35178023
http://dx.doi.org/10.3389/fneur.2021.811943
work_keys_str_mv AT wanghongwei updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT tianye updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT wujianwei updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT luosushan updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT zhengchaojun updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT sunchi updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT niecong updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT xiaxinlei updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT maxiaosheng updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT lyufeizhou updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT jiangjianyuan updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease
AT wanghongli updateonthepathogenesisclinicaldiagnosisandtreatmentofhirayamadisease